Methods for diagnosing and treating bicuspid aortic valve and/or aortopathies
Provided herein are methods for identifying and treating BAV disease and/or aortopathy in a subject, and methods of improving outcome in a subject. The subject may be asymptomatic of BAV disease and/or aortopathy, experiencing symptoms of BAV disease and/or aortopathy, have BAV disease and/or aortopathy, or be a blood relative of an individual having BAV disease and/or aortopathy. Levels of sRAGE in the subject's biological sample are determined, compared to a control biological sample, and used as an indicator for the presence and severity of BAV disease and/or aortopathies, a tool to screen family members, and an indicator of the proper surgical or treatment regimens.
1. A method of treating Bicuspid Aortic Valve (BAV) disease in a subject, the method comprising:
performing aortic valve replacement, performing ascending aorta surgery, administering a therapeutic compound, or a combination thereof to thereby treat the BAV disease in the subject,
wherein the subject has between about 600 pg/mL and about 1288 pg/ml of soluble Receptor for Advanced Glycation Endproducts (sRAGE) in a biological sample of the subject.
2. The method of claim 1 , wherein the biological sample of the subject contains at least 681 pg/mL of sRAGE.
3. The method of claim 1 , wherein the biological sample of the subject contains at least 15% greater sRAGE than a control biological sample.
4. The method of claim 3 , wherein the control biological sample is from a subject with a tricuspid aortic valve (TAV).
5. The method of claim 1 , further comprising imaging the aortic valve of the subject.
6. The method of claim 5 , wherein the imaging is echocardiography, color Doppler transesophageal echocardiography, cardiac magnetic resonance imaging, computerized tomography, or a combination thereof.
7. The method of claim 1 , wherein the administering a therapeutic compound reduces symptoms of the BAV disease.
8. The method of claim 1 , wherein the biological sample is blood.
9. The method of claim 1 , wherein between about 600 pg/mL and about 1288 pg/ml of sRAGE in the biological sample identifies the subject as having BAV with specificity of about 80% and sensitivity of about 70%.
10. A method for treating a subject with Bicuspid Aortic Valve (BAV) disease, the method comprising:
performing aortic valve replacement, performing ascending aorta surgery, administering a therapeutic compound, or a combination thereof to thereby treat the BAV disease in the subject,
wherein the BAV subject has at least 15% greater sRAGE than a control biological sample from a subject with a tricuspid aortic valve (TAV), and wherein the subject with BAV disease has between about 600 pg/mL and about 1288 pg/ml of soluble Receptor for Advanced Glycation Endproducts (sRAGE) in a biological sample of the BAV subject.
11. The method of claim 10 , wherein the biological sample of the BAV subject contains at least 681 pg/mL of sRAGE.
12. The method of claim 10 , further comprising imaging the aortic valve of the BAV subject.
13. The method of claim 12 , wherein the imaging is echocardiography, color Doppler transesophageal echocardiography, cardiac magnetic resonance imaging, computerized tomography, or a combination thereof.
14. The method of claim 10 , wherein the administering a therapeutic compound reduces symptoms of the BAV disease.
15. The method of claim 10 , wherein between about 600 pg/mL and about 1288 pg/ml of sRAGE in the biological sample identifies the subject as having BAV with specificity of about 80% and sensitivity of about 70%.
16. A method of treating Bicuspid Aortic Valve (BAV) disease in a subject, the method comprising:
performing valve replacement and ascending aorta surgery to thereby treat the BAV disease in the subject, wherein the subject has greater than about 1288 pg/ml of soluble Receptor for Advanced Glycation Endproducts (sRAGE) in a biological sample of the subject.
17. The method of claim 16 , wherein the biological sample of the subject contains at least 1765 pg/mL of sRAGE.
18. The method of claim 16 , wherein the biological sample of the subject contains at least 2209 pg/mL of sRAGE.
19. The method of claim 16 , wherein the biological sample of the subject contains at least 15% greater sRAGE than a control biological sample.
20. The method of claim 19 , wherein the control biological sample is from a subject with a tricuspid aortic valve (TAV).
21. The method of claim 16 , further comprising imaging the aortic valve of the subject.
22. The method of claim 21 , wherein the imaging is echocardiography, color Doppler transesophageal echocardiography, cardiac magnetic resonance imaging, computerized tomography, or a combination thereof.
23. The method of claim 16 , wherein the biological sample is blood.
24. The method of claim 16 , wherein greater than about 1288 pg/ml of sRAGE in the biological sample identifies the subject as needing aortic valve replacement and ascending aorta surgery with sensitivity of about 70% and specificity of about 75%.